Pepticom Ltd.

Amit Michaeli

Immanuel Lerner

Steffen Rupp

Anke Burger-Kentischer

The present invention provides new GABAreceptor-binding compounds that modify the activation of GABA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.

Positive allosteric modulators of GABAreceptor

A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes.

Growing community of inventors

Jerusalem, Israel

Amit Michaeli